Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHX NYSE:CANF NYSE:UPC NASDAQ:VAXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHXAthersys$0.00$0.01▼$1.99$833K-0.91.77 million shs460 shsCANFCan-Fite BioPharma$0.66-0.1%$0.84$0.63▼$3.12$2.34M1.06207,163 shs69,843 shsUPCUniverse Pharmaceuticals$3.75+6.8%$3.68$2.51▼$2,004.00$2.11M1.44257,966 shs430,898 shsVAXXVaxxinity$0.04+186.7%$0.02$0.00▼$0.10$5.45M15.196,837 shs193 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHXAthersys0.00%0.00%0.00%0.00%+42.86%CANFCan-Fite BioPharma+4.88%+1.07%+0.87%-40.34%-70.17%UPCUniverse Pharmaceuticals-1.96%-6.90%-0.43%-16.82%-99.82%VAXXVaxxinity-65.91%-25.00%+14,900.00%+14,900.00%+1,400.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHXAthersysN/AN/AN/AN/AN/AN/AN/AN/ACANFCan-Fite BioPharma3.026 of 5 stars3.55.00.00.01.80.01.3UPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHXAthersys 0.00N/AN/AN/ACANFCan-Fite BioPharma 3.00Buy$14.502,090.99% UpsideUPCUniverse Pharmaceuticals 0.00N/AN/AN/AVAXXVaxxinity 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATHX, VAXX, CANF, and UPC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.007/29/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHXAthersys$146K0.00N/AN/A($1.33) per share0.00CANFCan-Fite BioPharma$674K3.48N/AN/A$1.76 per share0.38UPCUniverse Pharmaceuticals$19.29M0.11N/AN/A$163.50 per share0.02VAXXVaxxinityN/AN/AN/AN/A$0.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHXAthersys-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/ACANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/AUPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/AVAXXVaxxinity-$56.93M-$0.45N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHXAthersysN/AN/AN/AN/AN/ACANFCan-Fite BioPharmaN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHXAthersysN/A0.060.06CANFCan-Fite BioPharmaN/A2.93N/AUPCUniverse PharmaceuticalsN/AN/AN/AVAXXVaxxinityN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHXAthersys19.35%CANFCan-Fite BioPharma21.00%UPCUniverse Pharmaceuticals0.18%VAXXVaxxinity82.95%Insider OwnershipCompanyInsider OwnershipATHXAthersys0.03%CANFCan-Fite BioPharma0.80%UPCUniverse Pharmaceuticals57.38%VAXXVaxxinity64.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHXAthersys2461.72 million61.70 millionNo DataCANFCan-Fite BioPharma83.54 millionN/ANot OptionableUPCUniverse Pharmaceuticals220563,000731,000Not OptionableVAXXVaxxinity90126.75 million45.55 millionNot OptionableATHX, VAXX, CANF, and UPC HeadlinesRecent News About These CompaniesBrain healthOctober 24, 2024 | newsweek.comNTreatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comIs Vaxxinity Inc (VAXX) Stock a Good Investment?September 19, 2024 | aaii.comACongress makes $4.5 trading stocks in a day; Here's the biggest winnersJuly 4, 2024 | finbold.comFVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?May 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 22, 2024 | investorplace.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | marketwatch.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockApril 19, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingMarch 28, 2024 | globenewswire.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | investorplace.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 27, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024March 7, 2024 | globenewswire.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | finance.yahoo.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024February 13, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaJanuary 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATHX, VAXX, CANF, and UPC Company DescriptionsAthersys NASDAQ:ATHXAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Can-Fite BioPharma NYSE:CANF$0.66 0.00 (-0.06%) Closing price 03:59 PM EasternExtended Trading$0.66 +0.00 (+0.03%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Universe Pharmaceuticals NYSE:UPC$3.75 +0.24 (+6.84%) Closing price 03:59 PM EasternExtended Trading$4.01 +0.26 (+6.93%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.Vaxxinity NASDAQ:VAXX$0.04 +0.03 (+186.67%) As of 10:08 AM EasternVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
